Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Lifetime prevalence of 5-6%. 12-month prevalence approximately 3%. More common in women (2:1 ratio). Frequently comorbid with depression.
CBT, SSRIs/SNRIs, buspirone, benzodiazepines (short-term). Response rates around 50-60%. Many patients experience only partial relief.
Psilocybin studies in cancer-related anxiety demonstrate significant and lasting anxiety reduction. LSD showed anxiolytic effects in the landmark Gasser et al. (2014) Swiss study. Mechanism may involve disruption of rumination circuits and enhanced emotional processing.
Griffiths et al. (2016): Psilocybin produced sustained anxiety decreases at 6-month follow-up in cancer patients. Gasser et al. (2014): LSD-assisted psychotherapy reduced anxiety in life-threatening illness.